Add to ORKGMature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cance
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...
Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the pro...
BACKGROUND: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known...
Because tamoxifen (TAM), a nonsteroidal antiestrogen, is routinely used in the adjuvant setting, oth...
BACKGROUND: Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stab...
PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...
Item does not contain fulltextPURPOSE: This phase III randomized open-label clinical trial was desig...
Based upon concepts derived from estrogen receptor studies, a phase II exploratory trial was conduct...
Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for p...
GA Walker,1 M Xenophontos,2 LC Chen,3 KL Cheung2 1Clinical Oncology, East Midlands Deanery, 2Breast ...
Breast cancer is the most prevalent type of cancer in women and responsible for significant female c...
Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letroz...
BACKGROUND Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as...
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine therapy ...
This European phase 3b, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a ...
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...
Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the pro...
BACKGROUND: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known...
Because tamoxifen (TAM), a nonsteroidal antiestrogen, is routinely used in the adjuvant setting, oth...
BACKGROUND: Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stab...
PURPOSE: This phase III randomized open-label clinical trial was designed to evaluate the efficacy a...
Item does not contain fulltextPURPOSE: This phase III randomized open-label clinical trial was desig...
Based upon concepts derived from estrogen receptor studies, a phase II exploratory trial was conduct...
Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for p...
GA Walker,1 M Xenophontos,2 LC Chen,3 KL Cheung2 1Clinical Oncology, East Midlands Deanery, 2Breast ...
Breast cancer is the most prevalent type of cancer in women and responsible for significant female c...
Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letroz...
BACKGROUND Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as...
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine therapy ...
This European phase 3b, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a ...
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...
Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the pro...
BACKGROUND: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known...